Codice QR

Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in Europe

BACKGROUND: Anecdotal information suggests that clinical practice regarding the use of putative hepatoprotective agents in TB treatment varies across countries in the WHO European Region. METHODS: Between November 2023 and May 2024, we conducted a standardised questionnaire survey on the use of puta...

Descrizione completa

Salvato in:
Autori principali: O. Kirakosyan, M. Reimann, A.B. Andersen, A. Bjarnason, Á. Bakos, A.M. Dyrhol-Riise, A.M. McLaughlin, C. Nita, D. Pieridou, D. Chesov, E.V. Davidavičienė, G. Günther, H. Atshemyan, I. Muylle, I. Solovic, J. Bruchfeld, K. Manika, L. Kuksa, L.R. Codecasa, M. Stosic, M. Skowroński, M.J. Makek, M. Fréchet Jachym, M. Knappik, M. Santin, N. Yatskevich, O. Konstantynovska, O. Akkerman, P. Svetina, P. Viiklepp, R. Duarte, S. Zeynel, T. Togonidze, T. Vasankari, V. Parris, Ş. Özkara, C. Lange, T.T. Brehm
Natura: Artigo
Lingua:Inglês
Pubblicazione: International Union Against Tuberculosis and Lung Disease (The Union) 2025-02-01
Serie:IJTLD Open
Soggetti:
hepatotoxicity
drug-induced liver injury
hepatitis
silibinin
ursodeoxycholic acid
Accesso online:https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2025/00000002/00000002/art00008
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi